

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2013

The Company announces the turnover and gross profit information, which has not been reviewed by its auditors, for the nine months ended 30 September 2013.

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2013 based on its management accounts which have not been reviewed by the auditors.

Turnover of the Group, which has not been reviewed by the auditors, for the nine months ended 30 September 2013 increased by 15.0% as compared with the same period of 2012 to HK\$2,043 million, with gross profit margin of 44.1% (for the nine months ended 30 September 2012: 42.8%) and in particular:

- Turnover of **intravenous infusion solution** for the first nine months in 2013 increased by approximately 25.6% as compared with the same period of 2012 to HK\$1,275 million, with gross profit margin of 45.3% (for the nine months ended 30 September 2012: 43.5%). Among which, sales of Non-PVC Soft Bag infusion solution was HK\$599.7 million, representing 52.3% of the total sales of intravenous infusion solution and an increase of 43.4% as compared with the same period of 2012; sales of PP Plastic Bottle infusion solution was HK\$354.1 million, representing 30.9% of the total sales of intravenous infusion solution and an increase of 3.5% as compared with the same period of 2012; and

- Turnover of **antibiotics finished medicines and non-antibiotics finished medicines** businesses for the first nine months in 2013 decreased by approximately 1.1% to HK\$387.9 million and increased by approximately 3.2% to HK\$380.5 million respectively as compared with the same period of 2012, with the gross profit margin of 42.2% (for the nine months ended 30 September 2012: 41.9%); among which, sales of Lijunsha amounted to HK\$228.7 million, represented an increase of 6.3% as compared with the same period of 2012; sales of Paiqi amounted to HK\$64.1 million, represented a decrease of 34.0% as compared with the same period of 2012; sales of Dobesilate amounted to HK\$71.0 million, represented an increase of 22.6% as compared with the same period of 2012; sales of Lixiding amounted to HK\$27.9 million, represented an increase of 5.7% as compared with the same period of 2012.

In terms of business segments analysis, intravenous infusion solution, antibiotics finished medicines and non-antibiotics finished medicines accounted for approximately 62.4%, 19.0% and 18.6% respectively of the total turnover of the Group, which has not been reviewed by the auditors, for the first nine months in 2013 (for the nine months ended 30 September 2012: 57.1%, 22.1% and 20.8% respectively).

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 22 October 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.